Share Facebook
Crohn's Disease Forum » Books, Multimedia, Research & News » IQWiG. No added benefit Vedoluzimab, adverse effects not properly tested.


11-08-2014, 05:26 AM   #1
kiny
Senior Member
 
kiny's Avatar
 
Join Date: Apr 2011
IQWiG. No added benefit Vedoluzimab, adverse effects not properly tested.

IQWiG. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, is an independent organisation employed by the German government to test and assess the benefits and safety of medication.

https://www.iqwig.de/download/A14-23...-35a-SGB-V.pdf

https://www.iqwig.de/en/press/press-...oven.6354.html

2014-10-15

Added benefit of vedolizumab is not proven


Dossier contained no suitable data for Crohn disease or ulcerative colitis

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups. According to the findings, such an added benefit is not proven because the dossier contained no suitable data for any of the two therapeutic indications.

Drug manufacturer presented no studies for Crohn disease

In its dossier, the manufacturer identified no randomized controlled trial (RCT) that directly compared vedolizumab with adalimumab for patients with moderately to severely active Crohn disease. Since it also conducted no indirect comparisons on the basis of RCTs, an added benefit of vedolizumab for the therapeutic indication Crohn disease is not proven.

Side effects were not analysed adequately

The indirect comparison was also unsuitable for a second reason: The adverse events in the vedolizumab study were not analysed adequately.

Last edited by kiny; 11-08-2014 at 05:42 AM.
11-08-2014, 07:06 AM   #2
JMC
Senior Member
 
JMC's Avatar
 
Join Date: Sep 2011
Location: London, United Kingdom
This is particularly interesting because CCUK announced the approval of Vedoluzimab to great fanfare only a few months ago. Clearly Crohn's patients deserve more from the biggest IBD charity in the UK than for it to be the PR department of certain pharmaceutical companies.
Reply

Crohn's Disease Forum » Books, Multimedia, Research & News » IQWiG. No added benefit Vedoluzimab, adverse effects not properly tested.
Thread Tools


All times are GMT -5. The time now is 02:28 AM.
Copyright 2006-2017 Crohnsforum.com